Ovarian cancer: is chemotherapy before surgery the way forward?

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2016-01-18 DOI:10.2217/IJE.15.30

S. Kehoe, Rami Fares, A. Phillips

引用次数: 0

Abstract

The treatment of advanced ovarian cancer is a combination of surgery and platin-based chemotherapy, with surgery traditionally the first intervention. Neoadjuvant therapy was only used in women who were deemed unfit for an operation. However, in recent years, two prospective randomized studies have evaluated the concept of neoadjuvant chemotherapy, and in both studies the results revealed that neoadjuvant chemotherapy with delayed surgery afforded similar survival rates compared with primary surgery but with reduced treatment-related morbidity. Thus, a novel evidence-based alternative approach to advanced ovarian cancer is now available.

查看原文本刊更多论文

卵巢癌:手术前化疗是未来的方向吗?

晚期卵巢癌的治疗是手术和以铂为基础的化疗的结合，传统上手术是第一个干预措施。新辅助治疗仅用于被认为不适合手术的妇女。然而，近年来，两项前瞻性随机研究评估了新辅助化疗的概念，两项研究的结果都表明，延迟手术的新辅助化疗与初次手术相比具有相似的生存率，但治疗相关的发病率降低。因此，一种新的基于证据的晚期卵巢癌替代方法现在是可用的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.